Skip to primary sidebar Search this website Home Company Products News & Releases Careers Contact Us MANAGEMENT TEAM Craig Collard — CEO Craig A. Collard has served as the Chief Executive Officer of Veloxis Pharmaceutics, Inc., a specialty pharmaceutical company, since December 2015. Prior to that, he served as the Chief Executive Officer and the chairman of the Board of Directors Cornerstone Therapeutics, Inc. (“Cornerstone”), a specialty pharmaceutical company, until February 2014, when Cornerstone was purchased by Chiesi Pharmaceuticals, Inc. Mr. Collard also served as Cornerstone’s Interim Chief Financial Officer from July 2010 through January 2011 and its President from October 2008 to September 2011. In March 2004, Mr. Collard founded Cornerstone BioPharma Holdings, Ltd. (the assets and operations of which were restructured as Cornerstone BioPharma in May 2005), and served as its President and Chief Executive Officer and a director from March 2004 to October 2008. Before founding Cornerstone BioPharma, Mr. Collard’s principal occupation was serving as President and Chief Executive Officer of Carolina Pharmaceuticals, Inc., a specialty pharmaceutical company he founded in May 2003. From August 2002 to February 2003, Mr. Collard served as Vice President of Sales for Verum Pharmaceuticals, Inc., a specialty pharmaceutical company in Research Triangle Park, North Carolina. From 1998 to 2002, Mr. Collard worked as Director of National Accounts at DJ Pharma, Inc., a specialty pharmaceutical company which was eventually purchased by Biovail Pharmaceuticals, Inc. Mr. Collard is a member of the board of directors of Veloxis Pharmaceuticals, Inc, a subsidiary of Asahi Kasei, Opiant Pharmaceutics, Inc., TerrAscend Corporation and Sierra Oncology. Ira Duarte — Chief Financial Officer Mark Hensley — Chief Commercial Officer Tunde Otulana, MD — Chief Medical Officer Ulf Meier-Kriesche, MD, FAST — Chief Scientific Officer Stacy Wheeler — VP, Operations Noel Barnard — VP, Legal and General Counsel Primary Sidebar COMPANY Overview Management Team Compliance NEWS & RELEASES Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor Sep 8, 2021 OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market Apr 26, 2021 Transplant Therapeutics Consortium Receives Acceptance of Letter-of-Intent for iBox Scoring System as a Reasonably Likely Surrogate Endpoint from the Biomarker Qualification Program Jun 18, 2020 READ MORE ©2021 All rights reserved. Veloxis Pharmaceuticals, Inc. US-UNB-2100005 7/21 Info@veloxis.com | 1-844-VELOXIS (835-6947), Monday-Friday, 9AM-7PM ET Sitemap | Contact | Privacy Policy | Disclaimer We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT